Compare Walt Disney Co (DIS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Neurocrine Biosciences Inc — how do they compare? Walt Disney Co trades at $107.01 (market cap $180.87B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Walt Disney Co is far larger — about 12.4× Neurocrine Biosciences Inc's market cap, and Walt Disney Co pays a 1.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DIS | NBIX | |
|---|---|---|
Market Cap | $180.87B | $14.60B |
Volume | 7,385,182 | 1,075,694 |
Sector | Media | Health |
52-Week High | $116.65 | $185.50 |
52-Week Low | $92.40 | $123.10 |
Typical Hold Time | 199 Days | 23 Days |
Enterprise Value | $221.73B | $14.61B |
Dividend Yield | 1.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.93% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $91.4B to $94.4B in 2025 and net income surging to $12.4B. Recent earnings beats and a $60B parks investment highlight strategic expansion. Analyst consensus remains strongly positive with a $125.67 price target, representing 17% upside potential from current levels.
Disney presents a compelling investment opportunity with accelerating profitability and strategic investments in experiences and streaming. Key risks include free cash flow pressure from elevated capital expenditures and competitive streaming landscape challenges. The stock's current valuation at 21.6x P/E appears reasonable given growth trajectory, though execution on content investments and margin expansion will be critical for sustained outperformance.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
